PRIA Logo™
117-hr-7008117th Congress

Pre-approval Information Exchange Act of 2022

Sponsored By: Representative Guthrie, Brett [R-KY-2]

Unknown

Summary

Pre-approval Information Exchange Act of 2022 This bill specifies that economic, scientific, or other product support information that is exchanged between drug manufacturers and health care entities (e.g., pharmacy benefit managers) about drug products before regulatory approval is not considered to be misbranding or prohibited premarket promotion if it relates to the product's investigational use and meets other specified criteria. The Government Accountability Office must study the use and effects of such information.

Personalized for You

How does this bill affect your finances?

Personalize government policy and PRIA will tell you what this bill means for your household, plus every other piece of legislation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.

Free to download

Bill Overview

No Economic Impacts Identified for this Bill

Sponsors & CoSponsors

Sponsor

Guthrie, Brett [R-KY-2]

KY • R

Cosponsors

  • Rep. Griffith, H. Morgan [R-VA-9]

    VA • R

    Sponsored 3/30/2022

Roll Call Votes

No roll call votes available for this bill.

View on Congress.gov
Back to Legislation